What is the 13F Pro Quality Score for INBX?

13F Pro ranks Inhibrx Biosciences, Inc. (INBX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View INBX's current score at https://13fpro.ai/research/INBX (free sign-up required for the full ranking).

Which hedge funds own the most INBX stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of INBX include PERCEPTIVE ADVISORS, VIKING GLOBAL INVESTORS, MORGAN STANLEY. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/INBX as soon as new 13F filings post.

Where does 13F Pro source INBX data?

All Inhibrx Biosciences, Inc. fundamentals and ownership data come directly from SEC EDGAR. Inhibrx Biosciences, Inc. files with the SEC under CIK 2007919. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is INBX in?

Inhibrx Biosciences, Inc. (INBX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is INBX research updated on 13F Pro?

INBX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Inhibrx Biosciences, Inc.(INBX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 2007919 INBX stock profile & AI dashboard →

13F Pro Quality Score

3.1/100

Rank #2,860 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

3.1/100

Profitability

0.6/100

Balance Sheet

0.8/100

Earnings Quality

30.0/100

Free Cash Flow

0.5/100

Institutional Flow

10.4/100

Revenue Scale

0.7/100

Dilution Risk

0.8/100

INBX Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Inhibrx Biosciences, Inc. (INBX), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores INBX at 3.1/100 on a 32-signal composite quality model, placing it at rank #2,860 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include free cash flow (0.5) and profitability (0.6), which score below median versus the broader universe. Shareholder dilution risk is elevated at 0.8/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Inhibrx Biosciences, Inc. reports net income of $-33.4M, free cash flow of $-38.0M. Top institutional holders of INBX by reported 13-F value include PERCEPTIVE ADVISORS, VIKING GLOBAL INVESTORS, MORGAN STANLEY, based on the most recent SEC filings. INBX trades on the Nasdaq exchange and files with the SEC under CIK 2007919. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate INBX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Inhibrx Biosciences, Inc. directly from SEC EDGAR. Inhibrx Biosciences, Inc.'s 13F Pro composite quality score has ranged between 3 and 48 since 2025, currently 3.1 — a declining long-term trajectory across 12 quarterly and live scoring snapshots.

✦

Fun facts about Inhibrx Biosciences, Inc.

Quirks, history, and lore behind INBX — the kind of stuff that makes a stock memorable.

1
The Basics
A clinical-stage biopharmaceutical company · listed on Nasdaq · headquartered in La Jolla, California · focused on developing novel protein therapeutics.
2
The Numbers
A small-cap biotech with minimal product revenue — it runs on collaboration deals and milestone payments while burning cash to fund its pipeline, as most clinical-stage biotechs do.
3
The History
The company was spun out as an independent public entity relatively recently, having previously operated as a subsidiary of a larger biotech before striking out on its own to pursue its pipeline full-time.
4
The Secret
Its platform specializes in engineering next-generation protein scaffolds — think antibodies but smarter — targeting rare and underserved diseases where existing drugs simply fall short.
5
The Lore
One of its lead programs targets alpha-1 antitrypsin deficiency, a rare genetic lung and liver disease that has frustrated drug developers for decades — a disease so niche even most doctors have to Google it.
6
The Giveaway
Its ticker is INBX, its name blends "inhibitor" with biosciences, and its pipeline of engineered protein drugs is being developed entirely out of La Jolla's biotech corridor.

▶ Think you know your stocks? Play the Daily Ticker

Net Income

Q1 2026

$-33.4M

Free Cash Flow

Q1 2026

$-38.0M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-27.8% YoY

$1.3MFY 2025

FY22 —FY23 $1.8MFY25 $1.3M

Net Income

+42.0% YoY

$-140.1MFY 2025

FY22 —FY23 $-241.4MFY25 $-140.1M

Operating Income

+38.4% YoY

$-135.0MFY 2025

FY22 —FY23 $-219.2MFY25 $-135.0M

EPS (Diluted)

+55.9% YoY

$-9.04FY 2025

FY22 —FY23 $-20.48FY25 $-9.04

Total Assets

-52.4% YoY

$146.5MFY 2025

FY22 —FY23 $307.9MFY25 $146.5M

Total Debt

-51.4% YoY

$100.6MFY 2025

FY22 —FY23 $207.0MFY25 $100.6M

Op. Cash Flow

+32.9% YoY

$-129.8MFY 2025

FY22 —FY23 $-193.3MFY25 $-129.8M

Metric	FY 2025	FY 2023	FY 2022
Revenue	$1.3M -27.8%	$1.8M	—
Net Income	$-140.1M +42.0%	$-241.4M	—
Operating Income	$-135.0M +38.4%	$-219.2M	—
EPS (Diluted)	$-9.04 +55.9%	$-20.48	—
Total Assets	$146.5M -52.4%	$307.9M	—
Total Debt	$100.6M -51.4%	$207.0M	—
Operating Cash Flow	$-129.8M +32.9%	$-193.3M	—

AI Insight: INBX Financial Trends

Inhibrx burned through $8M in equity to negative territory by Q1 2026 while debt tripled, with no meaningful revenue generation offsetting $33M quarterly net losses.

• Revenue remains essentially zero across all periods; Q2 2025 showed $1M but fell back to $0M by Q3 2025 and Q1 2026.

• Net losses stabilized around $33–35M/quarter in Q3 2025–Q1 2026 versus $43–48M in late 2024, but operating cash burn persists.

• Total debt surged from $0M in Q2 2024 to $175M by Q1 2026; equity collapsed from $219M to negative $21M over same period.

⚠ Negative shareholder equity of $21M signals insolvency risk; company now relies entirely on debt for runway.

⚠ Operating cash flow deteriorated to negative $38M in Q1 2026, the worst in the dataset, despite stable net losses.

AI Insight: INBX Ratio Trends

Inhibrx remains deeply unprofitable with negative ROIC and ROA; leverage spiked to 12.58x D/E in Q4 2025 before data gap.

• ROA improved from -89.7% in Q4 2025 to -72.7% in Q1 2026, but remains severely negative.

• D/E ratio surged from 1.04 in Q1 2025 to 12.58 in Q4 2025, signaling sharply increased financial risk.

• ROIC ranged from -65.3% to -98.9% across 2025; TTM ROIC at -79.9% shows sustained value destruction.

⚠ Extreme leverage spike (12.58x) in Q4 2025 demands clarification—likely one-time financing event or covenant breach.

⚠ No operating or net profit margins reported; unable to assess gross-to-net conversion or operating leverage.

Get alerted when INBX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Inhibrx Biosciences, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of INBX

PERCEPTIVE ADVISORS LLC
$97.0M1,442,707 sh
VIKING GLOBAL INVESTORS LP
$96.7M1,437,705 sh
MORGAN STANLEY
$84.9M1,263,078 sh
Sanofi
$77.8M1,157,926 sh
HighTower Advisors, LLC
$58.5M870,200 sh
BlackRock, Inc.
$53.7M798,898 sh
STATE STREET CORP
$37.0M550,845 sh
VANGUARD CAPITAL MANAGEMENT LLC
$32.7M486,422 sh
Sofinnova Ventures Inc
$27.3M406,029 sh
Capital Research Global Investors
$26.4M392,847 sh

Fund	Value	Shares
PERCEPTIVE ADVISORS LLC	$97.0M	1,442,707
VIKING GLOBAL INVESTORS LP	$96.7M	1,437,705
MORGAN STANLEY	$84.9M	1,263,078
Sanofi	$77.8M	1,157,926
HighTower Advisors, LLC	$58.5M	870,200
BlackRock, Inc.	$53.7M	798,898
STATE STREET CORP	$37.0M	550,845
VANGUARD CAPITAL MANAGEMENT LLC	$32.7M	486,422
Sofinnova Ventures Inc	$27.3M	406,029
Capital Research Global Investors	$26.4M	392,847

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put INBX on your watchlist

Track score changes the day Inhibrx Biosciences, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is INBX a good stock to buy?

13F Pro's AI-powered analysis of Inhibrx Biosciences, Inc. (INBX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for INBX are available on the INBX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own INBX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling INBX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Inhibrx Biosciences, Inc.'s investment landscape.